pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
183
stories
10d
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
11d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
11d
STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
stat
11d
The FDA’s Overton era, and dispatches from Shanghai
stat
11d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
11d
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
stat
12d
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
biospace
13d
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
13d
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
13d
Celldex sinks as safety concerns cloud immune drug results
biopharma dive
13d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
13d
2026 IPO blitz continues with 4 new biotech filings
biospace
14d
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpoints
15d
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
17d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
17d
STAT+: Roche expands its Boston footprint with new research center
stat
18d
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
stat
18d
Two more biotechs, Marea and North Immunology, do reverse mergers
endpoints
18d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
18d
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
18d
STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom
stat
18d
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
18d
STAT+: A Sellas immunotherapy study, long delayed, will end in failure
stat
18d
STAT+: A biotech hedge fund births a new immunology company
stat
18d
Roche turns to Dualitas to find new bispecific approaches for immunology
endpoints
18d
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
18d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
19d
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
20d
5 biotechs braving the commercial waters with product launches
biospace
20d
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
← prev
page 2 of 7
next →
